Multigene Panel Testing Increases the Detection of Clinically-Actionable Mutations in Ovarian Cancer Patients
Utilizing MGPT in ovarian cancer patient allows for the identification of a significant number of pathogenic mutations in genes other than BRCA1/2.
Approximately 93% of pathogenic mutations were identified in genes with associated NCCN® cancer risk management guidelines.
The identification of clinically-actionable mutations in genes beyond BRCA1/2 allows for more personalized management recommendations of ovarian cancer patients and their at-risk relatives
Authors: Tara Namey; Holly LaDuca; Amal Yussuf; Jessica Profato